2023 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãß°èÇмú´ëȸ 1ÀÏÂ÷ : 2023-11-16
±³À°ÀÏÀÚ : 2023-11-16
±³À°Àå¼Ò : ¼Ò³ëº§°æÁÖ EASTŸ¿ö ÁöÇÏ 1Ãþ ±×·£µåº¼·ý
±³À°ÁÖÁ¦ : 2023 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãß°èÇмú´ëȸ 1ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ
´ã´çÀÚ : ¹Ú¼Ò¹Î
¿¬¶ôó : 02-398-5055
À̸ÞÀÏ : office@kscpt.org
±³À°Á¾·ù : ³»°ú, ¸¶ÃëÅëÁõÀÇÇаú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, ¾à¸®ÇÐ
Âü¼®¿¹»óÀÎ : 300¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 4 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 250,000¿ø
ºñ°í "[»çÀüµî·Ï]
Á¤È¸¿ø 18¸¸¿ø / ÁØȸ¿ø 8¸¸¿ø / ºñȸ¿ø ÀÏ¹Ý 22¸¸¿ø / ºñȸ¿ø Çлý 12¸¸¿ø
[ÇöÀåµî·Ï]
Á¤È¸¿ø 20¸¸¿ø / ÁØȸ¿ø 10¸¸¿ø / ºñȸ¿ø ÀÏ¹Ý 25¸¸¿ø / ºñȸ¿ø Çлý 15¸¸¿ø"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11¿ù 16ÀÏ ¼Ò³ëº§ °æÁÖ EAST Ÿ¿ö ÁöÇÏ 1Ãþ ±×·£µåº¼·ý 13:15~13:40 mRNA vaccine overview ³²Àçȯ(°¡Å縯´ëÇб³)
±³À°½Ã°£ 11¿ù 16ÀÏ ¼Ò³ëº§ °æÁÖ EAST Ÿ¿ö ÁöÇÏ 1Ãþ ±×·£µåº¼·ý 13:40~14:05 mRNA vaccine : From COVID-19 to mRNA based Therapeutics °ÅÂÁø(¢ß·¹³ªÀÓ)
±³À°½Ã°£ 11¿ù 16ÀÏ ¼Ò³ëº§ °æÁÖ EAST Ÿ¿ö ÁöÇÏ 1Ãþ ±×·£µåº¼·ý 14:05~14:30 ³ª³ë¾à¹°Àü´Þü ¿øöÈñ(·¹¸ð³Ø½º)
±³À°½Ã°£ 11¿ù 16ÀÏ ¼Ò³ëº§ °æÁÖ EAST Ÿ¿ö ÁöÇÏ 1Ãþ ±×·£µåº¼·ý 14:45~15:10 Discovery of vaccine candidate against SARS-CoV-2 ±èõ»ý(Çѱ¹ÈÇבּ¸¿ø)
±³À°½Ã°£ 11¿ù 16ÀÏ ¼Ò³ëº§ °æÁÖ EAST Ÿ¿ö ÁöÇÏ 1Ãþ ±×·£µåº¼·ý 15:10~15:35 ½Å±Ô ³ª³ë¸®Æ÷Á» ¸é¿ªÁõ°Á¦ Ç÷§Æû °³¹ß ÀÌÁ¤À±(¢ßÀ¯¹ÙÀÌ¿À·ÎÁ÷½º)
±³À°½Ã°£ 11¿ù 16ÀÏ ¼Ò³ëº§ °æÁÖ EAST Ÿ¿ö ÁöÇÏ 1Ãþ ±×·£µåº¼·ý 15:35~16:10 ÆÒµ¥¹Í »óȲ¿¡¼ÀÇ ¹é½Å ÀÓ»ó½ÃÇè–º£Æ®³²ÀÇ °æÇèÀ» Áß½ÉÀ¸·Î Dr. Thiem (NIHE)
±³À°½Ã°£ 11¿ù 16ÀÏ ¼Ò³ëº§ °æÁÖ EAST Ÿ¿ö ÁöÇÏ 1Ãþ ±×·£µåº¼·ý 16:20~16:45 Optimal Dosing Strategies for Novel Bispecific Fusion Proteins Targeting IL2R¥â¥ãand CTLA4 Based on Translational Mathematical Modeling 䵿¿ì(¿¬¼¼´ëÇб³)
±³À°½Ã°£ 11¿ù 16ÀÏ ¼Ò³ëº§ °æÁÖ EAST Ÿ¿ö ÁöÇÏ 1Ãþ ±×·£µåº¼·ý 16:45~17:10 Translational Research for Model Informed Precision Medicine in Antimicrobial Pharmacotherapy Á¶¿ë¼ø(ÀÎÁ¦´ëÇб³)
±³À°½Ã°£ 11¿ù 16ÀÏ ¼Ò³ëº§ °æÁÖ EAST Ÿ¿ö ÁöÇÏ 1Ãþ ±×·£µåº¼·ý 17:10~17:35 PK/PD modeling of GLP-1 agonists: practice and implications ¹è¼öÇö(¾ÖÀÓ½º¹ÙÀÌ¿À»çÀ̾ð½º)
±³À°½Ã°£ 11¿ù 16ÀÏ ¼Ò³ëº§ °æÁÖ EAST Ÿ¿ö ÁöÇÏ 1Ãþ ±×·£µåº¼·ý 17:35~18:00 Bridging from Preclinical to Clinical in Oncology Drug Development À̼ҿµ(¼¿ï´ëÇб³)